A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Hodgkin lymphoma and other malignancies that express the CD30 protein have been the scourge of oncologists for decades. For ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Hodgkin’s lymphoma is rapidly expanding, driven by innovative clinical advancements and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, ...

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings from ...

The global Cutaneous T-cell Lymphoma (CTCL) market is witnessing significant growth due to increasing disease prevalence, particularly among older populations, and advancements in diagnostic ...